ABSTRACT: The use of exogenous proteins as intracellular probes and therapeutic agents is in its infancy. A major hurdle has been the delivery of native proteins to an intracellular site of action. Herein, we report on a compact delivery vehicle that employs the intrinsic affinity of boronic acids for the carbohydrates that coat the surface of mammalian cells. In the vehicle, benzoxaborole is linked to protein amino groups via a "trimethyl lock." Immolation of this linker is triggered by cellular esterases, releasing native protein. Efficacy is demonstrated by enhanced delivery of green fluorescent protein and a cytotoxic ribonuclease into mammalian cells. This versatile strategy provides new opportunities in chemical biology and pharmacology.
T he delivery of proteins and other macromolecules to an intracellular site is made difficult by cellular membranes. 1 Extensive efforts have led to the development of effective delivery systems that invoke cell-penetrating peptides, 2−6 antibodies, 7 ligands for natural receptors, 8 dendrimers, 9 functionalized polymers, 10, 11 liposomes, 12 or nanoparticles 13, 14 and even enable targeting to subcellular organelles. 15, 16 Nonetheless, extant strategies often inflict proteins with low biological activity, 11,17−19 instability in a physiological context, 20, 21 or immunogenicity in vivo, 22, 23 or employ vehicles that are recalcitrant to biodegradation. 24 Boronic acids are physiologically benign Lewis acids that react spontaneously and reversibly with 1,2-and 1,3-diols to form five-and six-membered cyclic boronic esters, respectively. 25, 26 The dynamic covalent bonding of boronic acids/ esters can facilitate the delivery of cargo into cells, which are coated with a diol-rich glycocalyx. To exploit that attribute, polymers, nanoparticles, and noncovalent assemblies have been decorated with phenylboronic acid and other arylboronic acids. 27, 28 Recently, we showed that boronic acids can be advantageous when conjugated directly to a protein. 18 The ensuing formation of transient boronate esters with the glycocalyx enhances cellular delivery. To date, this approach has relied on the irreversible modification of a target protein, with ensuing compromises. For example, our previous work installed boronic acids by the irreversible amidation of enzymic carboxyl groups, which led to the loss of 83% of catalytic activity. 18 An ideal delivery system based on boronic acids (or, indeed, any moiety) conveys native cargo, and is thus "traceless."
We sought to use a boronic acid and an immolative linker to promote the delivery of native proteins into a cell. As a boronic acid, we chose 2-hydroxymethylphenylboronic acid (benzoxaborole), which has higher affinity than does phenylboronic acid for the glycopyranosides that are abundant in the glycocalyx. 18, 28, 29 As an immolative linker, we chose the ohydroxydihydrocinnamic acid derivative known as the trimethyl lock (TML). After being triggered, the TML exhibits extremely high lactonization rates to release a cargo of interest (Scheme 1). 30−34 The TML has been used for a wide variety of applications in chemistry and pharmacology 35 but not as an immolative linker on a protein. We chose ester hydrolysis as the means to trigger lactonization of the TML, as esterases are abundant inside, but not outside, of human cells 36−38 and underlie the action of numerous prodrugs. 39 We equipped our TML scaffold with an N-hydroxysuccinimide ester for chemoselective conjugation to amino groups, 17 such as those at the N terminus and on the side chain of lysine residues, which have a ∼6% abundance in proteins. 40 Thus, our delivery vehicle (B-TML−NHS ester) has three modules: benzoxaborole, an esterase-activated TML linker, and an NHS ester ( Figure 1A ).
We synthesized B-TML-NHS ester convergently in 10 steps by extending a known procedure. 41 Then, we characterized its ability to enhance the cellular internalization of green fluorescent protein (GFP) (Scheme 2), which has distinctive fluorescence and an inability to enter mammalian cells. 42 Overnight incubation at ambient temperature with 100-fold excess of B-TML-NHS ester in 3:1 PBS/acetonitrile yielded 3 ± 1 labels per protein ( Figures 1B and S1 ). The number of labels in the B-TML-GFP conjugate did not decrease after a month of storage in PBS ( Figure S2) , consistent with the stability observed for other TML conjugates. 43−45 Labeling was, however, "bioreversible." Incubation with a lysate from Chinese hamster ovary (CHO) K1 cells removed all of the labels from B-TML-GFP ( Figure 1B) .
Next, we compared the uptake of B-TML-GFP and unlabeled GFP by CHO K1 cells. After a 4-h incubation, we observed a dramatic increase in the cellular uptake of B-TML-GFP ( Figure 1C ). The fluorescence in microscopy images was largely punctate, suggesting that B-TML-GFP was taken up via an endosomal pathway ( Figure 1D ). Co-localization of this bright punctate staining with a stain for transferrin was consistent with this conclusion ( Figure S3) . After a 24-h incubation, the fluorescence intensity had increased significantly beyond the level measured at 4 h, indicating that the conjugate was stable in the presence of serum, which was a component of the cell-culture medium ( Figure S4 ).
To confirm that the boronic acid moiety was responsible for the difference in cellular entry, we performed two control experiments. First, we modified GFP with a vehicle (Ac-TML-NHS ester) that lacks the benzoxaborole functionality ( Figure  1A) , yielding a level of labeling similar to that from B-TML-NHS ester ( Figure S1 ). When incubated with cells for 4 h, Ac-TML-GFP was taken up comparably to unlabeled GFP rather than to B-TML-GFP ( Figure 1C and D) . These data indicate that the enhanced delivery upon treatment with B-TML-NHS ester is not due to the mere modification of lysine residues or to interactions with the TML portion of B-TML. Next, we repeated the cellular uptake experiments with B-TML-GFP in the presence of fructose, which has a K a of 336 M −1 for benzoxaborole. 18 We observed a significant decrease in GFP uptake in the presence of fructose, apparent with both confocal microscopy and flow cytometry (Figure 2A and B) . Again, these data indict the boronic acid portion of B-TML-GFP as being responsible for cellular uptake.
Finally, we sought to test the efficacy of B-TML as a delivery vehicle to the cytosol. To do so, we employed an enzymic cytotoxinthe G88R variant of ribonuclease A, which must reach cytosolic RNA to manifest its toxic activity. 46, 47 After labeling the ribonuclease by the same procedure used to label GFP, we observed an average of 1.6 ± 0.7 labels per molecule of protein ( Figure S5 ). This lower labeling is consistent with GFP (19 lysine residues) having more amino groups than does the ribonuclease (12 lysine residues). Again, we found that the labeling was bioreversible, as incubation with a CHO K1 cell lysate removed all of the labels ( Figure S6 ). Finally, we assayed the ability of B-TML-ribonuclease and unlabeled ribonuclease to inhibit the proliferation of K-562 cells, which are derived from a human myelogenous leukemia line. We found that the pendant boronic acids resulted in a decrease in the IC 50 value (Figure 3) , indicative of more cytotoxin reaching the cytosol.
We conclude that covalent modification of proteins with B-TML-NHS ester can increase their ability to enter mammalian cells. Importantly, this modification is bioreversible. The irreversible modification of a protein can compromise its utility. 11,17−23 In contrast, endogenous cellular enzymes revert modification with B-TML.
The bioreversibility of our delivery vehicle provides new opportunities. The sulfhydryl groups of cysteine residues have long been used for this purpose because their mixed disulfides suffer reduction within the cytosol. 48, 49 Recently, we found that appropriately tuned diazo compounds can esterify protein carboxyl groups, providing a second type of bioreversible modification. 50, 51 In this work, we report on a bioreversible modification of protein amino groups that is distinct from others 52−54 
